Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Peter T. Daley-Yates"'
Publikováno v:
Journal of Asthma and Allergy
Intranasal corticosteroid (INCS) therapy is the preferred treatment option for allergic rhinitis (AR). Although all INCSs for the treatment of AR are considered safe and effective, differences in potency, molecular structure features and physicochemi
Publikováno v:
Pulmonary Pharmacology & Therapeutics. 77:102171
To investigate the pharmacokinetics and effects on the hypothalamic-pituitary-adrenal (HPA) axis of mometasone furoate (MF), fluticasone propionate (FP) and fluticasone furoate (FF).Study 1: Fourteen healthy participants received inhaled and intraven
Autor:
Dave Singh, Noushin Brealey, Peter T. Daley-Yates, Brian Keppler, Shaila S. Shabbir, Neil Barnes
Publikováno v:
Airway pharmacology and treatment.
This is the first study to compare the relative systemic metabolomic and lipidomic bioactivity dose-responses for ICS. Plasma for metabolomic and lipidomic analysis was obtained from 54 subjects (GSK study 203162, NCT02991859) who received weekly esc
Autor:
Daren Austin, Shaila S. Shabbir, Dave Singh, Neil Barnes, Peter T. Daley-Yates, Tim Harrison, Noushin Brealey, Sebin Thomas, B. Kumar
Publikováno v:
61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V..
Autor:
Neil Barnes, Tim Harrison, Daren Austin, Dave Singh, Sebin Thomas, Noushin Brealey, Peter T. Daley-Yates, Shaila S. Shabbir
Publikováno v:
British journal of clinical pharmacology. 87(2)
Aims To compare the airway potency, systemic activity and therapeutic index of three inhaled corticosteroids that differ in glucocorticoid receptor binding affinity, physicochemical and pharmacokinetic properties. Methods This escalating-dose, placeb
Autor:
Teresa Fuller, Claire Ambery, Adam Hughes, Adrian Pereira, Graeme Young, Aili L. Lazaar, David Ramsay, Peter T. Daley-Yates, Frans van den Berg
Publikováno v:
Clinical Pharmacology in Drug Development
Clin Pharmacol Drug Dev
Clin Pharmacol Drug Dev
Inhaled batefenterol is an investigational bifunctional molecule for the treatment of chronic obstructive pulmonary disease. The excretion balance and pharmacokinetics of batefenterol using [14C]‐radiolabeled drug administered orally and as intrave
Publikováno v:
Expert Review of Respiratory Medicine. 11:763-778
Introduction: Many trials have been published comparing inhaled corticosteroid (ICS) treatments in asthma. However, mixed results necessitate the summarization of available evidence to aid in decision-making. Areas covered: This systematic review eva
Autor:
Bharath Kumar, Peter T. Daley-Yates, Daren Austin, Tim Harrison, Neil Barnes, Shaila S. Shabbir, Dave Singh, Noushin Brealey, Sebin Thomas
Publikováno v:
Airway pharmacology and treatment.
FF is an inhaled corticosteroid (ICS) with higher glucocorticoid receptor affinity, tissue permeability and lung retention than other ICS. We investigated whether these attributes improve the therapeutic index (TI), defined as systemic activity to to
Autor:
James Fingleton, Richard Beasley, Amanda Baines, Peter T. Daley-Yates, George Bardsley, Kylie Riddell, Shashidhar Joshi, Philippe Bareille
Publikováno v:
60. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V..
Publikováno v:
Clinical Pharmacology in Drug Development. 5:399-407
To investigate the pharmacokinetics of inhaled batefenterol (BAT) and fluticasone furoate (FF) given alone or in combination via ELLIPTA® dry powder inhaler (DPI-E), and BAT monotherapy via DISKUS® DPI (DPI-D). In this open-label, 6-way crossover s